Cellectis shares break through their €1.35 resistance before retreating 5.5%
The Parisian biotech reached an intraday high before giving back much of its gains. The session coincides with the publication of its third-quarter results.
A level breached intraday, then abandoned in the morning session
Cellectis shares fell 5.7% to €1.27 intraday, after breaking above their €1.35 resistance to an intraday high of €1.38.
The stock has dropped back below that level, so the €1.35 zone remains intact for now. The pullback follows a sharp weekly rebound, +24.3% over seven days, which barely offsets a 49% decline over three months.
The share price remains above its 20-day moving average at €1.04 (+22.5%), but below its 50-day moving average at €1.34 (-4.9%): the recent rebound brought the stock back into contact with this average without reclaiming it. The 15% surge observed the previous day had already pushed the stock toward this zone.
Third-quarter results due this Thursday, as the CAC 40 rises
Cellectis publishes its third-quarter 2026 results today, an event the stock approaches after strong recent volatility. The preclinical data presented at the end of October in Hamburg, showing a 75% reduction in triglycerides in mice, had fueled the rebound begun at the end of October.
Meanwhile, the CAC 40 gains 0.73% and the SBF 120 0.7%, so the day's decline is specific to the stock.
Cellectis is listed on two markets: the ordinary share in Paris, eligible for the PEA, and the ADS on the Nasdaq, at a one-for-one ratio. The November 12 session therefore revolves around the release of the accounts and the €1.35 threshold.
